Cav2.2 x ADRA1 x VMAT2 x β1-adrenergic receptor

Phase IIb, randomized, double-blind, placebo-controlled study in parallel groups assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington's Disease with choreic movements.

Phase IIa study to evaluate the efficacy and safety of SOM3355 in chorea movements associated with Huntington's disease